問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

更新時間：2025-12-16

王主科Wang, Jou Kou
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years 2 個月

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王主科

List

15Cases

2019-05-01 - 2022-04-25

Phase III

Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects

  • Condition/Disease

    Fontan-palliated Adult and Adolescent Subjects

  • Test Drug

    Macitentan

Participate Sites
1Sites

Recruiting1Sites

2017-03-31 - 2022-07-01

Phase II/III

Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril in pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction.

  • Condition/Disease

    pediatric patients with heart failure due to systemic left ventricle systolic dysfunction.

  • Test Drug

    LCZ696

Participate Sites
3Sites

Recruiting3Sites

2015-05-21 - 2020-02-28

Phase III

Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years

  • Condition/Disease

    venous thromboembolism

  • Test Drug

    Pradaxa Capsules

Participate Sites
2Sites

Terminated2Sites

2013-11-01 - 2020-07-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-12-31 - 2019-12-18

Phase II/III

Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.

  • Condition/Disease

    Hemorrhage

  • Test Drug

    達栓普注射液/輸注液

Participate Sites
2Sites

Terminated2Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB